Y. Choi

1987–2025 年に発表

別表記
Y Choi
123
論文数
28,988
被引用数
78
h 指数
113
i10 指数

被引用数

Y. Choi の年別被引用数1989 年: 被引用 1 件1990 年: 被引用 1 件1991 年: 被引用 1 件1995 年: 被引用 1 件1997 年: 被引用 4 件1998 年: 被引用 8 件1999 年: 被引用 2 件2000 年: 被引用 13 件2001 年: 被引用 5 件2002 年: 被引用 13 件2003 年: 被引用 12 件2004 年: 被引用 44 件2005 年: 被引用 43 件2006 年: 被引用 42 件2007 年: 被引用 59 件2008 年: 被引用 56 件2009 年: 被引用 51 件2010 年: 被引用 54 件2011 年: 被引用 38 件2012 年: 被引用 93 件2013 年: 被引用 105 件2014 年: 被引用 121 件2015 年: 被引用 97 件2016 年: 被引用 172 件2017 年: 被引用 202 件2018 年: 被引用 220 件2019 年: 被引用 587 件2020 年: 被引用 711 件2021 年: 被引用 677 件2022 年: 被引用 547 件2023 年: 被引用 421 件2024 年: 被引用 526 件2025 年: 被引用 235 件2026 年: 被引用 11 件1992〜1994 年は被引用が無いため表示していません1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 1,302 件、この内訳の 16.5%アメリカ合衆国: 引用元論文 1,232 件、この内訳の 15.6%日本: 引用元論文 574 件、この内訳の 7.3%ドイツ: 引用元論文 443 件、この内訳の 5.6%イタリア: 引用元論文 410 件、この内訳の 5.2%韓国: 引用元論文 357 件、この内訳の 4.5%イギリス: 引用元論文 340 件、この内訳の 4.3%フランス: 引用元論文 268 件、この内訳の 3.4%スペイン: 引用元論文 232 件、この内訳の 2.9%スイス: 引用元論文 229 件、この内訳の 2.9%インド: 引用元論文 169 件、この内訳の 2.2%カナダ: 引用元論文 167 件、この内訳の 2.1%
0%16.5%その他 27.5%

分野

  • Medicine57%
  • Physics and Astronomy15.3%
  • Biochemistry, Genetics and Molecular Biology14.3%
  • Environmental Science2.6%
  • Computer Science2.3%
  • Immunology and Microbiology2.3%
  • その他6.2%

トピック

  • Gastric Cancer Management and Outcomes8%
  • Cancer Immunotherapy and Biomarkers6.3%
  • Particle physics theoretical and experimental studies4.6%
  • Thyroid Cancer Diagnosis and Treatment3%
  • Gastrointestinal Tumor Research and Treatment2.6%
  • Quantum Chromodynamics and Particle Interactions2.5%
  • その他73%

共著者

全論文

検索で開く
  1. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 2,279

  2. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , - The Lancet 2012 被引用: 1,721

  3. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

    著者: , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 885

  4. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

    著者: , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 346

  5. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project

    著者: , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2017 被引用: 479

  6. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeeyun Lee, Won Ki Kang, Sung Hoon Kim, Sung Hoon Noh, Gordon B. Mills, Seon‐Young Kim, Jaffer A. Ajani, Ju‐Seog Lee, Seon‐Young Kim, Jaffer A. Ajani, Ju‐Seog Lee, Ju‐Seog Lee - Nature Communications 2018 被引用: 464

  7. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jian Fang, Wei Li, Jianying Zhou, Jun Zhao, Ying Cheng, Chih-Hsin Yang, Gee‐Chen Chang, Yuh‐Min Chen, Te‐Chun Hsia, Chih‐Feng Chian, Cheng-Ta Yang, Chin‐Chou Wang, Sang‐We Kim, Keunchil Park, Dong‐Wan Kim, Byoung Chul Cho, Ki Hyeong Lee, Young‐Chul Kim, Ho Jung An, In Sook Woo, Y. Choi, Sang Won Shin, Jong Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Ross A. Soo, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles, Martín Emilio Lázaro Quintela, Enriqueta Felip Font, Anne‐Marie C. Dingemans, Lynne A. Bui - The Lancet Respiratory Medicine 2020 被引用: 258

  8. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2019 被引用: 231

  9. Veterinary antibiotics in animal waste, its distribution in soil and uptake by plants: A review

    著者: , - The Science of The Total Environment 2016 被引用: 457

  10. Nanomedicine for glioblastoma: Progress and future prospects

    著者: , , , , , , , - Seminars in Cancer Biology 2022 被引用: 40

  11. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2021 被引用: 123

  12. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 294

  13. Gene Expression Signature–Based Prognostic Risk Score in Gastric Cancer

    著者: , , , , , , , , , , , , , , , - Clinical Cancer Research 2011 被引用: 369

  14. Global loss of cellular m 6 A RNA methylation following infection with different SARS-CoV-2 variants

    著者: , , , , , , , , , , , , , , - Genome Research 2023 被引用: 37

  15. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 243

  16. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2023 被引用: 23

  17. Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.

    著者: , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 17

  18. Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial

    著者: , , , , , , , , , , , , , , , - European Journal of Cancer 2020 被引用: 69

  19. Observation of a Narrow Charmoniumlike State in ExclusiveB±→K±π+π−J/ψDecays

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , L. Y. Dong, A. Drutskoy, S. Eidelman, V. Eiges, J. Flanagan, C. Fukunaga, K. Furukawa, N. Gabyshev, T. Gershon, B. Golob, H. Guler, R. Guo, C. Hagner, F. Handa, T. Hara, N. C. Hastings, H. Hayashii, M. Hazumi, L. Hinz, Y. Hoshi, W.-S. Hou, Y. Hsiung, Hsuan‐Cheng Huang, T. Iijima, K. Inami, A. Ishikawa, R. Itoh, M. Iwasaki, M. Iwasaki, J. H. Kang, S.U. Kataoka, N. Katayama, H. Kawai, T. Kawasaki, H. Kichimi, E. Kikutani, H. J. Kim, Hyunwoo Kim, J. H. Kim, S. K. Kim, K. Kinoshita, H. Koiso, P. Koppenburg, S. Korpar, P. Križan, P. Krokovny, Suneel Kumar, A. Kuzmin, J. S. Lange, G. Leder, S. H. Lee, T. Lesiak, S.-W. Lin, D. Liventsev, J. MacNaughton, D. Majumder, F. Mandl, D. Marlow, T. Matsumoto, Shinichiro Michizono, T. Mimashi, W. Mitaroff, K. Miyabayashi, H. Miyake, D. Mohapatra, G. R. Moloney, T. Nagamine, Y. Nagasaka, T. Nakadaira, T. Nakamura ほか 74 名 - Physical Review Letters 2003 被引用: 1,970

  20. Search for lepton-flavor-violating τ decays into three leptons with 719 million produced τ+τ− pairs

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , H. Ha, J. Haba, B.-Y. Han, H. Hayashii, Y. Hoshi, W.-S. Hou, Y. Hsiung, H. J. Hyun, T. Iijima, R. Itoh, M. Iwabuchi, M. Iwasaki, M. Iwasaki, J. H. Kang, T. Kawasaki, C. Kiesling, H. J. Kim, H.O. Kim, J.H. Kim, S.K. Kim, Y.I. Kim, Y.J. Kim, B. R. Ko, P. Kodyš, S. Korpar, P. Križan, P. Krokovny, T. Kumita, A. Kuzmin, P. Kvasnička, Y.-J. Kwon, S.-H. Kyeong, J. S. Lange, M. J. Lee, Soohyung Lee, J. Li, Cheng Liu, Y. Liu, D. Liventsev, R. Louvot, A. Matyja, S. McOnie, K. Miyabayashi, H. Miyata, R. Mizuk, T. Mori, E. Nakano, M. Nakao, H. Nakazawa, Z. Natkaniec, S. Nishida, K. Nishimura, O. Nitoh, S. Ogawa, T. Ohshima, S. Okuno, S. L. Olsen, P. Pakhlov, G. Pakhlova, C.W. Park, H. Park, H.K. Park, M. Piccolo, M. Petrič, L. E. Piilonen, A. Poluektov, M. Röhrken, S. Ryu, H. Sahoo, Kenichi Sakai ほか 35 名 - Physics Letters B 2010 被引用: 477

  21. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer

    著者: , , , , , , , , , - Clinical Cancer Research 2017 被引用: 141

  22. Study ofe+e−→π+π−J/ψand Observation of a Charged Charmoniumlike State at Belle

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Y. Choi, D. Cinabro, J. Dalseno, M. Danilov, Z. Doležal, Z. Drásal, A. Drutskoy, D. Dutta, Kaustav Dutta, S. Eidelman, D. Epifanov, H. Farhat, J. Fast, M. Feindt, T. Ferber, A. Frey, V. Gaur, N. Gabyshev, S. Ganguly, R. Gillard, Y. M. Goh, B. Golob, J. Haba, K. Hayasaka, H. Hayashii, Y. Horii, Y. Hoshi, W.-S. Hou, Y. Hsiung, H. J. Hyun, T. Iijima, K. Inami, A. Ishikawa, R. Itoh, M. Iwasaki, D. Joffe, T. Julius, D. H. Kah, J. H. Kang, T. Kawasaki, C. Kiesling, H. J. Kim, J. B. Kim, J. H. Kim, K. T. Kim, M. J. Kim, Y. J. Kim, K. Kinoshita, J. Klucar, B. R. Ko, P. Kodyš, S. Korpar, P. Križan, P. Krokovny, T. Kuhr, Y.-J. Kwon, J. S. Lange, Soohyung Lee, J. Li, Y. Li, J. Libby, C. Liu, P. Lukin, D. Matvienko, K. Miyabayashi, H. Miyata, R. Mizuk, G. B. Mohanty, A. Moll, R. Mussa ほか 91 名 - Physical Review Letters 2013 被引用: 741

  23. Population Genetic Structure in Indian Austroasiatic Speakers: The Role of Landscape Barriers and Sex-Specific Admixture

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Biology and Evolution 2010 被引用: 179

  24. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

    著者: , , , , , , , , - The Oncologist 2016 被引用: 121